Stay on Top of 340B this Summer
We are looking forward to connecting with you during the 340B Coalition Summer Conference being held July 15-17 in Washington, D.C. RxStrategies is proud to be a Pinnacle Sponsor for the event. Our team will be connecting with key leaders to discuss 340B comprehensive solutions, and share ideas on how to keep your 340B program on the right…
Meet RxStrategies in Philadelphia for 340B Summit
Jonathan Ghenn and Rhodie Smith will be attending and meeting with industry leaders during the 4th Annual Covered Entities 340B Summit hosted by World Congress, May 16 – 17 in Philadelphia, PA. RxStrategies is proud to be a Supporting Sponsor for the Summit. This event brings HRSA grantees and covered entities together to discuss the…
Simplify 340B with Dashboard Analytics
Our powerful analytics platform provides users with robust and insightful visibility into their 340B program. With an intuitive, cloud-based platform, an advanced reporting machine, and reliable analytics, RxStrategies’ Dashboard Analytics solution simplifies your entire 340B program. Real-time accumulator views, WAC-spend analyses, robust drill-down capabilities, and custom report creations provide our users access to the exact…
340B Program Compliance. Achieve More With Intuitive Solutions.
It was great to connect with industry leaders during the 15th Annual 340B Coalition Winter Conference! As a pharmacist, clinic director, or C-suite executive, one of your top priorities is to provide safe and cost-effective care and ensure regulatory compliance. RxStrategies understands the complexities of the 340B program and recognizes the importance of open communication…
340B Insider – December 2018
Welcome to the December edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. Visit our website to read more. 340B INDUSTRY NEWS Read below for recent news from 340B Health. THE U.S. HOUSE PASSES BILL TO KEEP DRUG COMPANIES FROM OVERCHARGING MEDICAID The bipartisan bill, from…
Clinical Insights: November 7, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Lorbrena® (lorlatinib) – New Drug Approval – November 2, 2018 – The Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with…
Clinical Insights: August 30, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval AltrenoTM (tretinoin) – August 24, 2018 – Ortho Dermatologics, one of the largest prescription dermatology healthcare businesses in the world, announced that the U.S. Food and Drug…
Clinical Insights: July 19, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval SymtuzaTM (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) – July 17, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration…
Clinical Insights: June 21, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Moxidectin – June 13, 2018 – Medicines Development for Global Health (MDGH) and the World Health Organisation Special Programme for Research and Training in Tropical Diseases…
Clinical Insights: June 4, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Olumiant® (baricitinib) – June 1, 2018 – Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has approved the 2-mg…
Clinical Insights: May 23, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Doptelet® (avatrombopag) – May 21, 2018 – The Food and Drug Administration approved avatrombopag (Doptelet®, AkaRx Inc.) for thrombocytopenia in adults with chronic liver disease scheduled to…
Clinical Insights: May 16, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Retacrit® (epoetin alfa-epbx) – New Biosimilar Drug Approval – May 15, 2018 – U.S. Food and Drug Administration approved Retacrit®(epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin…